Reference
Bommer C, et al. Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland. European Journal of Health Economics : 12 Nov 2021. Available from: URL: https://doi.org/10.1007/s10198-021-01396-9
Rights and permissions
About this article
Cite this article
More invasive prophylactic strategies worth it for BRCA1/2 mutation-positive women. PharmacoEcon Outcomes News 892, 16 (2021). https://doi.org/10.1007/s40274-021-08211-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08211-z